<DOC>
	<DOCNO>NCT00215709</DOCNO>
	<brief_summary>This pilot study design determine feasibility safety administer docetaxel various dose level bi-weekly schedule old men hormone refractory prostate cancer .</brief_summary>
	<brief_title>Bi-Weekly Administration Docetaxel Older Men With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>The information obtain trial help determine feasibility safety administer docetaxel various dose level bi-weekly schedule patient population . If data phase I trial encouraging , phase II trial conduct assess efficacy dose schedule .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>age ≥ 65 year ; histologically confirm adenocarcinoma prostate ; metastatic disease ; unresponsive refractory hormonal therapy , define least 1 follow criterion : progression bidimensionally measurable disease ; progression evaluable measurable disease ( bone scan ) ; least 2 consecutive rise PSA least 1 week apart ; patient must serum testosterone level &lt; 50 ng/mL time study entry . For patient medically castrate , lutenizing hormone release hormone analog must continue maintain testicular suppression ; prior nonsteroidal antiandrogens ( flutamide , ketoconazole , bicalutamide , nilutamide ) allow disease progression occur . No evidence response antiandrogen withdrawal within 4 week patient treat flutamide , ketoconazole , nilutamide 6 week patient treat bicalutamide ; chemotherapy naïve ; full recovery effect prior surgery radiation therapy . At least 4 week since radiation therapy ; ECOG performance status 02 ; adequate kidney , liver , bone marrow function ; sign studyspecific inform consent form . Concurrent chemotherapy immunotherapy ; Patients receive investigational drug within 4 week registration ; Prior concurrent malignancy ( surgically treat carcinoma situ cervix squamous basal cell carcinoma skin ) within precede five year ; Serious medical psychiatric illness would prevent informed consent ; Life expectancy &lt; 3 month ; Active uncontrolled bacterial , viral , fungal infection condition correct control ; Known hypersensitivity study drug drug formulate polysorbate 80 .</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>elderly</keyword>
</DOC>